Livebiotech economyWestern cycleAnchors pending

Between 2026 and 2028, overcapacity will trigger 3 or more major mRNA vaccine plant closures?

As of 2 Oct · 12:00 UTCResolves 31 Dec 20283 movers2 pressure moments
Timeline A · Plants CloseReality
80%
Crowd 55%Gap 0

By late 2028, mRNA vaccine makers have shut down at least three major manufacturing plants across North America and Europe. Moderna closes its Switzerland facility and consolidates U.S. production; Novavax exits manufacturing entirely; BioNTech shuts a secondary European site. The collapse follows two years of oversupply — Covid boosters plateau, RSV vaccine uptake disappoints, and flu-mRNA combos cannibalize rather than expand the market. Fixed costs of $500M+ per plant become unsustainable when utilization drops below 40%.

Timeline B · Capacity HoldsReality
20%
Crowd 45%Gap 0

The mRNA vaccine industry retains all major plants through 2028, though some operate at reduced capacity. Moderna and BioNTech pivot to combination vaccines (flu-RSV-Covid in single shots), contract manufacturing for third parties, and secure government stockpile contracts that keep utilization above 60%. Novavax stabilizes under new ownership or partnership. Seasonal demand patterns and emerging infectious disease preparedness sustain enough throughput to avoid facility closures.

crowd 55
The quiet paththe one nobody’s watching

A new pandemic pathogen emerges in 2026–2027, converting excess capacity into urgent shortage instead of closure risk.

6%
The read
Reality still leans toward Plants Close.

Reality favors Plants Close — the pressures holding that outcome in place are stronger than the counter-pull. The main thing that could shift this is COVID vaccine demand floor.

Where reality is heading

A, 80% bandCrowd today
Projected reality support to 31 Dec 2028A rises from 41% to about 52% with an 80% band of 33 to 71. B falls from 53% to about 44%. Quiet path near 4 to 6%. Crowd today: A 55%.100%7550250Crowd today · A 55%A ~52%B ~44%P ~4%NowJan 2027Jan 202831 Dec 2028
Reality crosses toward A in early 2028. Today’s crowd number sits at the top of A’s band, possible but optimistic. View as table

The movers, ranked by leverage

01
Rising-power eliteConsciousness-pattern template for an actor-class in a rising power whose decisions on technology, military doctrine, trade posture, and institutional strategy bend the trajectory of a rising-vs-ruling cycle. Operates in the B_leak boundary channel per AMENDMENT 47 §MCA-1 — what actors are reaching for.
leverage 78
Rising-power moves tend to accelerate rivalry trajectories.
02
Global health institutionActor-class for institutions whose role is pathogen surveillance, pandemic preparedness, vaccine R&D coordination, and global health governance. WHO, CEPI, Pandemic Fund, Africa CDC, Quadripartite AMR body, GAVI, national CDCs operating at international mandate. Direction typically Timeline-A on health-system-stability cycle via codification work; Timeline-B when the institution degrades or is rejected (decodification per Form 6).
leverage 55
Global health bodies codify or decay depending on legitimacy inflows.
03
Collective pull shiftMarket-class: discontinuous move in collective attention + capital toward an outcome, measurable in prediction markets (Polymarket / Kalshi / Manifold / Metaculus / PredictIt) and sector-rotation flows. Per AMENDMENT 47 §MCA-2, this IS the B_leak = consciousness measurement instrument where it covers an outcome. Direction contextual depending on which outcome the pull targets.
leverage 50
Prediction markets reprice when collective pull on an outcome moves.

What would change our mind

Signals toward A
  • COVID vaccine demand floor crossing the threshold toward Plants Close
  • mRNA therapeutics pipeline maturity readings confirming the Plants Close direction
  • Pandemic preparedness contracts trajectory bending toward Plants Close
  • Fresh readings from Moderna 2024 revenue (2024-12-31) — $3.2B, down 70% from 2022 peak of $19.3B pointing toward Plants Close
Signals toward B
  • COVID vaccine demand floor holding against the shift toward Capacity Holds
  • mRNA therapeutics pipeline maturity readings confirming the Capacity Holds direction
  • Pandemic preparedness contracts trajectory bending toward Capacity Holds
  • Fresh readings from Novavax near-bankruptcy (2023-12-01) — Capacity-adjustment stress pointing toward Capacity Holds

Pressure moments

US-China decoupling crystallizessemiconductor supply-chain split (chip-fab geography, EDA stack adoption) · telecom-equipment market split (Huawei + ZTE share of RoW markets) · payment-rail adoption (SWIFT vs CIPS)
3-7 year crystallization phase
High
AI capability discontinuityfrontier model benchmark saturation + new benchmark emergence · autonomous-agent task-completion rate on real-world browser/code benchmarks · model-collapse regression indicators
3-9 months at observable-step window; prelude years
High

Evidence